	{{#each Dates}}				
		{{#Event}}	
		<div class="block spotblock spot grid-1-3 event--link" data-date="{{month}}" data-location="{{location}}" data-disease="{{disease}}">
            <div class="spotContainer visual headingColor-color2 headingAlignment-left headingStyle-normal iconColor-color1 textColor-color1 textAlignment-left textStyle-normal linkColor-color1 backgroundColor-color7 spotLayout-topimage trigger-change" itemscope="" itemtype="http://schema.org/CreativeWork">
                <div class="content {{bg}} content_310">
                    <div class="content-restrict" style="word-wrap: break-word;">
                        <div itemprop="text">
                            <div class="event_spot_block red">
                                <div class="header">
                                    <h4 class="underline">{{start-date}}</h4>
                                    <h4 class="underline">{{address}}</h4>
                                    <h4>{{area}}</h4>
                                </div>
                                <h2 class="title" itemprop="headline"><a class="eventLink" href="{{link}}">{{title}} <span>&#9654;</span></a></h2>
                            </div>
                        </div>
                    </div>

                </div>
            </div> 
        </div>
						
		{{/Event}}	
	{{/each}}


<div class="text--block">
<div class="grid-1-2 borderRight paddingRight">
<h5>When prescribed Cosentyx 150 mg* as their first-line biologic:</h5>
<h5 class="pinkText">FUTURE 2</h5>
<img alt="" src="/admui/CMS/Content/siteassets/gb-portal/cosentyx-section/sustained-benefits-in-psa/img/futuretwoalt.jpg,,85941?epieditmode=False" />
<h5 class="pinkText">FUTURE 1</h5>
<img alt="" src="/admui/CMS/Content/siteassets/gb-portal/cosentyx-section/sustained-benefits-in-psa/img/futureone.jpg,,85937?epieditmode=False" /></div>
<div class="grid-1-2 paddingLeft">
<h5>When prescribed Cosentyx 300 mg:**</h5>
<h5 class="pinkText">FUTURE 2</h5>
<img alt="" src="/admui/CMS/Content/siteassets/gb-portal/cosentyx-section/sustained-benefits-in-psa/img/futuretwo.jpg,,85938?epieditmode=False" /></div>
<div class="clear">&nbsp;</div>
<h5>Patients with PsA have reported lower health-related quality of life scores around bodily pain vs. patients with RA<sup>11</sup></h5>
<a class="footNoteButton" href="#"> Show Footnotes </a>
<div class="hide">
<p class="figureText">Results from overall FUTURE 2 population. Missing values imputed as non-response to Week 24. Observed data presented at Weeks 52 and 104. 24 weeks, N=100, 1 year, N=88; 2 years, N=56 Patients in the FUTURE 1 study received intravenous loading doses of Cosentyx and continued with subcutaneous doses as maintenance<br /> Intravenous loading is not licensed for use. Primary endpoint was met. Patients in the FUTURE 2 study received subcutaneous loading and maintenance dosing. Missing values imputed as non-response to Week 24, observed data presented at Year 2 and Year 3. 24 weeks, N=63; 2 years, N=53; 3 years, N=120<br /> *150 mg dose of Cosentyx is licensed in PsA patients who are biologic-naïve with mild or no psoriasis<sup>12</sup><br /> **300 mg dose of Cosentyx is licensed in patients with concomitant moderate-to-severe psoriasis or who are anti-TNF inadequate responders12</p>
</div>
</div>

<div class="spotContainer visual headingColor-color2 headingAlignment-left headingStyle-normal iconColor-color1 textColor-color1 textAlignment-left textStyle-normal linkColor-color1 backgroundColor-color7 spotLayout-topimage trigger-change add-pink iconRight" itemscope="" itemtype="http://schema.org/CreativeWork">
    <div class="content">
        <div class="event_spot_block">
            <div class="header pink sectionHeading">
                <h4>Cosentyx provided patients with the opportunity for complete resolution of dactylitis and enthesitis through 2 years<sup>1,5</sup></h4>
            </div>
        </div>
    </div>
</div>
<div class="text--block">
<img src="/siteassets/gb-portal/cosentyx-section/sustained-benefits-in-psa/img/graphsix.jpg" alt="graph" />
<a class="footNoteButton" href="#"> Show Footnotes </a>
<div class="hide">
<p class="figureText">*p&#60;0.01; **p&#60;0.05 vs. placebo.<br>
Resolution of dactylitis and enthesitis amongst the overall population of patients with these symptoms at baseline. Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52; multiple imputation applied to missing values for data for Week 104. Data from overall patient population.</p>
<h5>What difference could the freedom from dactylitis and enthesitis bring to your patients’ lives?</h5>
</div>
</div>